# Kamada Q3 2026 Earnings Report

> Kamada boosts Q3 revenue by 11% with KEDRAB market share at 50% in U.S.
- Title: Kamada Q3 2026 Earnings Report · The Motley Fool | Shortify
- Summary: Kamada boosts Q3 revenue by 11% with KEDRAB market share at 50% in U.S. Kamada reported $52 million Q3 revenue, 11% YoY growth, and $15.2 million adjusted…
- Keywords: kamada, kedrab, q3 2026, revenue, adjusted ebitda, market share, biosimilar, plasma supply, distribution segment, dividend, The Motley Fool
- Source: The Motley Fool — https://fool.com/earnings/call-transcripts/2026/11/09/kamada-kmda-q3-2026-earnings-call-transcript
- Author: Motley Fool Transcribing
- Published: 2026-11-09T16:53:24+00:00
- Read time: 2 min
- Topics: kamada, kedrab, q3 2026, revenue, adjusted ebitda, market share, biosimilar, plasma supply, distribution segment, dividend, finance, money
## Q3 Revenue
Total revenue reached $52 million for the third quarter, increasing 11% year over year.
## Adjusted EBITDA
Adjusted EBITDA stood at $15.2 million, a 30% year over year increase with 29% margin.
## Net Income
Net income totaled $8 million for the quarter, representing 51% year over year growth.
## 2026 Revenue Guidance
2026 revenue guidance increased to $205 million to $208 million from previous range of $200 million to $205 million.
## Distribution Segment
Distribution segment revenue reached $24.1 million for first nine months, a 35% year over year increase.
## KEDRAB Market Share
KEDRAB holds at least 50% market share in U.S. supported by CDC health advisory.
## Plasma Supply Agreement
Plasma supply agreement worth $50 million over three years to supply normal source plasma.
## Biosimilar Revenue Guidance
Biosimilar revenue expected to reach $10 million annually by 2028 and $20 million to $25 million by 2030.
## Dividend Payments
Dividend payments totaled $32.3 million for 2026, including $0.14 per share for Q4.
## Gross Margins
Gross margins increased to 45% for Q3, up from 42% last year due to improved product mix.
## Operating Expenses
Operating expenses rose to $13 million in Q3, up from $11.9 million due to expanded commercial operations.
## Nine-Month Net Income
Nine-month net income reached $21.4 million, a 29% year over year increase.
## Nine-Month Adjusted EBITDA
Nine-month adjusted EBITDA totaled $40.9 million, a 20% year over year increase with 27% margin.
## Nine-Month Revenue
Nine-month revenue reached $152.2 million, a 12% year over year increase driven by KEDRAB, VARIZIG, and HEPAGAM B.
## 2027 Financial Projections
Management projects double-digit growth for both revenues and profitability in 2027.
## Biosimilar Pipeline
At least two additional biosimilar products scheduled for commercial launch in Israeli market next year.
## Key takeaway

Kamada reported $52 million Q3 revenue, 11% YoY growth, and $15.2 million adjusted EBITDA with 29% margin.